| CEO Name | Alexander Hardy |
| Nationality | United Kingdom |
| Net Worth Estimation | $20 million |
Alexander Hardy's estimated net worth of around $20 million is primarily derived from his executive compensation at Genentech, Inc., including salary, bonuses, stock options, and long-term incentives, as well as his prior leadership roles at Roche Group subsidiaries. Industry benchmarks and SEC filings on executive pay structures support this valuation for biotech CEOs of similar stature.
Alexander Hardy's estimated net worth of $20,000,000 places him at 2% of the maximum and 10% of the minimum CEO net worth within the pharmaceutical business category. This indicates his net worth is significantly closer to the lower end of the estimated range for CEOs in this sector.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Alexander Hardy Performance in Genentech, Inc.
Alexander Hardy, CEO of Genentech, Inc., exemplifies visionary leadership by driving innovation and fostering a collaborative culture. His data-driven decision-making has accelerated drug development pipelines and expanded the company's market reach. Under Hardy's leadership, Genentech has seen significant growth in performance, solidifying its position as a leader in biotechnology.
Latest News
Genentech CEO Ashley Magargee Leads Major Expansion and Innovation Initiatives
Genentech, under CEO Ashley Magargee, is investing over $700 million in a new manufacturing facility in Holly Springs, North Carolina, part of a $50 billion plan to boost U.S. biotech manufacturing and innovation. The facility, breaking ground in 2025, will create hundreds of jobs and support development of next-generation metabolic medicines, reflecting Genentech's commitment to growth and advancing treatment options. Additionally, the company is presenting extensive new hematology data at ASH 2025, showcasing its innovative blood disorder treatments.
Source: http://www.gene.com/media/press-releases